The ARFGAP3 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the HT29 human colorectal adenocarcinoma line. This heterogeneous cell pool carries targeted disruptions of the ARFGAP3 gene, creating a loss-of-function model for studying ARFGAP3-dependent processes. The polyclonal format avoids clonal bias and allows robust functional studies. This model is particularly suited for research in membrane trafficking and cancer biology.
HT29 cells are an established epithelial model of colorectal adenocarcinoma, widely used for cancer research and intestinal barrier studies. They express epithelial markers, harbor oncogenic mutations (e.g., APC, TP53), and can form polarized monolayers or differentiate into enterocyte-like cells. This well-characterized background provides a relevant context for investigating gene function in colorectal cancer.
ARFGAP3 functions as a GTPase-activating protein (GAP) that specifically catalyzes GTP hydrolysis on ARF1, thereby triggering COPI coat disassembly from Golgi membranes. This reaction is critical for retrograde vesicle-mediated transport from the Golgi apparatus to the endoplasmic reticulum. Upstream regulators include ARF1-GTP itself, SRC kinase, protein kinase C (PKC), and Golgi stress signals that sense membrane curvature. Upon activation, ARFGAP3 interacts with the COPI coatomer complex and Golgi matrix proteins such as GOLGA2 (GM130) and USO1 (p115). Downstream, it generates ARF1-GDP, leading to coat dissociation and facilitating Golgi enzyme retention and recycling of transport machinery. Additional pathway constituents encompass SNARE proteins (STX5, GOSR1) and p24 family cargo receptors that mediate vesicle fusion and cargo selection.
Disruption of ARFGAP3 in the HT29 colorectal adenocarcinoma model severely impacts Golgi architecture and secretory pathway integrity, enabling dissection of how trafficking defects promote tumorigenesis. HT29 cells depend on Golgi function for processing and transport of adhesion proteins, growth factor receptors, and matrix metalloproteinases; consequently, ARFGAP3 knockout can attenuate cell polarity, migration, and invasiveness. Moreover, retrograde trafficking disruptions may alter the subcellular distribution of drug targets and efflux transporters, offering insights into acquired drug resistance. By combining ARFGAP3 loss with the HT29 genetic background, researchers can examine Golgi stress responses and signaling rewiring in an epithelial cancer context.
Researchers can use these cells for immunofluorescence staining of Golgi markers (GM130, TGN46), western blotting for ARF1 and COPI components, and RT-qPCR for ARFGAP3 expression. Additional assays include luciferase-based secretion measurements, live-cell Golgi dispersion imaging, and cell migration/invasion tests. For more details or ordering, contact Ascent Research.
